CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating

Neutral
AI Analysis

Summary

Leerink Partners increased its price target for Quest Diagnostics from $240 to $244 while maintaining an Outperform rating.

Importance:2/10
Sentiment:
0.10
price_targetanalyst_ratingdiagnostics
Related Companies

Read the original article

Published by yahoo_finance on July 15, 2026 4:02 PM

Read Original